Dr.SAMYUKTA SADASIVAN K, S20266
Purpose:To evaluate the efficacy and safety of monotherapy with Tacrolimus 0.03% ointment in vernal keratoconjunctivitis(VKC) in paediatric patients.
Methods:This prospective, non-randomised study included 45subjects, 5-15years newly diagnosed with VKC, graded on a 4point scale of symptoms and signs, treated with Tacrolimus0.03% ointment and followed up for 8months. The primary efficacy endpoint was the change in the composite sign score. Failure was defined as additional requirement of topical steroids in the 1stmonth. Safety was based on the incidence of adverse events.
Results:The mean composite symptom score reduced from 6.76±2.2 at baseline to 0.71±1.6 and the mean composite sign score reduced from 10.22±3.5 to 1.18±1.3 at 8months, p-value<0.001. Thus 88.9% showed significant improvement and 11.1% failed treatment. The only adverse effect was a transient stinging effect.
Conclusion:Tacrolimus0.03% ointment monotherapy is safe and effective in the treatment of VKC in children.
Leave a Comment